15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 26 firms covering Alnylam Pharmaceuticals Inc, 21 rate it Buy or better, 5 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $377.00 to $485.00, so the covering firms are broadly aligned. The average target of $413.00 sits 43% above the current $288.58. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 51% this year and 30% next, consensus EPS building from about $2.41 next quarter toward $13.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS26 ratings
Moderate Buy
Strong Buy00%
Buy2181%
Hold519%
Sell00%
Strong Sell00%
Based on 26 analysts giving stock ratings to Alnylam Pharmaceuticals Inc.
As of Jul, 21 of 26 firms rate ALNY a Buy (5 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ALNY EPS & revenue forecast
EPS · NEXT QUARTER
$2.41
Range $1.64 – $3.74 · 13 analysts · -17% YoY
Next period, 13 analysts expect Alnylam Pharmaceuticals Inc to earn $2.41 a share (range $1.64 – $3.74), versus $2.90 a year earlier. Full-year consensus is $9.42, growing to $13.44 the year after.
REVENUE · NEXT QUARTER
$1.5B
Range $1.4B – $1.6B · 13 analysts · +19% YoY
Revenue is expected to reach $1.5B (range $1.4B – $1.6B), +19.0% year-over-year. Full-year consensus is $5.6B, rising to $7.2B next year.
Top analysts covering Alnylam Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ALNY.
#1
Jessica Fye
JP Morgan · Rank #64
Buy
$400.00+38.6% to target
Overall win rate
52%
+ Follow
#2
Keay Nakae
Chardan Capital · Rank #130
Buy
$425.00+47.3% to target
Overall win rate
41%
+ Follow
#3
Joseph Stringer
Needham · Rank #168
Buy
$510.00+76.7% to target
Overall win rate
36%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #177
Buy
$450.00+55.9% to target
Overall win rate
38%
+ Follow
#5
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$485.00+68.1% to target
Overall win rate
35%
+ Follow
ALNY stock forecast FAQ
What is ALNY's average 12-month price target?+
The 9 analysts with a live target average $413.00 for Alnylam Pharmaceuticals Inc over the next 12 months, ranging from a $485.00 high to a $377.00 low.
Is ALNY stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 26 analyst ratings, 21 are Buy or Strong Buy, 5 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ALNY?+
The Street-high target is $485.00 (HC Wainwright & Co.), and the Street-low is $377.00 (Wells Fargo). The average of all 9 active targets is $413.00.
How many Wall Street analysts cover ALNY?+
26 analysts have an active rating on Alnylam Pharmaceuticals Inc, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering ALNY?+
Among analysts who currently cover ALNY, Jessica Fye of JP Morgan has the strongest overall Quantellect track record (Rank #64). Their current call is Buy with a $400.00 target.
What is Alnylam Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $2.41 per share (range $1.64 – $3.74) across 13 analysts. Full-year EPS is projected at $9.42, rising to $13.44 the following year.
How much revenue is Alnylam Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $1.5B (range $1.4B – $1.6B). Full-year revenue is projected at $5.6B, growing to $7.2B next year.
Have analysts been upgrading or downgrading ALNY lately?+
As of Jul, 21 of 26 firms rate ALNY a Buy (5 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ALNY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
